Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
$TGTX raises BRIUMVI FY'25 U.S. net product revenue target to $570M - $575M (prior guidance of $560M) Raises total global revenue target to apprx $585M vs. prior guidance of $575M
$TGTX Earnings: - Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million - Net income was $28.2 million and $33.2 million for the three and six months ended June 30, 2025, respectively, compared to net income (loss) of $6.9 https://t.co/sP6VLzFb45
$TGTX Earnings out Second quarter 2025 total revenue of $141.1 million, including BRIUMVI U.S. net revenue of $138.8 million Raises Guidance Raises BRIUMVI U.S. net product revenue target to $570 - $575 million for the full year 2025 (prior guidance of $560 million for full year
TG Therapeutics reported second-quarter 2025 revenue of $141.1 million, falling short of the $146.4 million analysts expected. Diluted earnings per share were $0.17, also below the $0.19 consensus forecast. Net income for the period was $28.2 million. Sales were driven almost entirely by BRIUMVI, the company’s anti-CD20 therapy for relapsing multiple sclerosis, which generated $138.8 million in U.S. net revenue for the quarter. Buoyed by continued uptake of BRIUMVI, the New York-based drugmaker raised its full-year 2025 guidance. It now projects U.S. BRIUMVI sales of $570 million to $575 million, up from $560 million previously, and expects total global revenue of roughly $585 million, compared with a prior forecast of $575 million.
